De Novo

De Novo Special Controls: What They Mean for Your Device and Every Competitor That Follows

By Andre D. Butler, medical device regulatory consultant, CQA, CCRP  ·  reviewed November 2026  ·  ← All Insights

De Novo Special Controls: What They Mean for Your Device and Every Competitor That Follows

Photo by Brett Jordan on Unsplash

When a De Novo Grant Is More Than a Green Light

Winning a De Novo authorization from FDA is a significant milestone — but founders and regulatory teams often treat it primarily as a clearance event. Pop the champagne, update the website, and move on. That instinct misses something critical: a De Novo grant does not just authorize your device. It creates law.

Under 21 CFR Part 860, Subpart D, FDA's De Novo classification order establishes a new device type, assigns it a product code, and — most consequentially — codifies the special controls that any manufacturer must meet to bring a substantially equivalent device to market via 510(k). The order is published in the Federal Register, incorporated by reference into the Code of Federal Regulations, and becomes the enforceable regulatory framework for every device in that newly created classification. Understanding what special controls actually require, and how they extend far beyond your own device, is essential for any company that has navigated or is planning a De Novo submission.

What Special Controls Actually Are — And Are Not

FDA defines special controls in Section 513(a)(1)(B) of the Federal Food, Drug, and Cosmetic Act as measures that, together with general controls, provide reasonable assurance of safety and effectiveness for a Class II device. They are not suggestions. They are not guidance documents you can acknowledge and deviate from with a footnote. They are the minimum technical, clinical, and performance requirements a device must satisfy to qualify for the classification.

Special controls established through a De Novo order typically include some combination of the following:

  • Performance testing requirements — specific bench tests, software verification and validation protocols, electromagnetic compatibility standards, or biocompatibility evaluations under ISO 10993 that must be completed and documented.
  • Labeling requirements — mandatory contraindications, warnings, intended use language, and sometimes user training specifications that must appear in device labeling.
  • Clinical performance criteria — defined sensitivity, specificity, or other clinical endpoints that must be met with supporting data, often tied to specific patient populations or clinical settings.
  • Post-market surveillance obligations — requirements for complaint handling, real-world performance monitoring, or registry participation that persist through the device lifecycle.
  • Software and cybersecurity requirements — increasingly common in modern De Novo orders, particularly for SaMD and connected devices, often referencing FDA's own guidance on software lifecycle processes or the 2023 Cybersecurity guidance.

The specific controls are enumerated in the classification order itself and, once finalized, in the classification regulation. Reviewing both documents together — not just the press release or the FDA authorization letter — is non-negotiable for any technical team preparing a downstream 510(k).

How Special Controls Bind Future 510(k) Submitters

Here is where the downstream implications become commercially and legally significant. Once FDA grants a De Novo and the classification regulation is established, any manufacturer seeking 510(k) clearance using the De Novo device as a predicate must demonstrate substantial equivalence — which means demonstrating that their device meets the same special controls.

This is not optional, and it is not negotiable through creative predicate arguments. Under 21 CFR 807.87(f), a 510(k) must include performance data demonstrating that the device meets applicable special controls. If a competitor's device cannot satisfy the testing thresholds, labeling requirements, or clinical performance criteria established in your De Novo order, their 510(k) will not be cleared on that predicate.

What this means in practice:

  • Your De Novo order becomes the technical benchmark your competitors must clear. If you set aggressive performance thresholds — and FDA accepted them — those thresholds now apply to everyone.
  • If a competitor attempts to cite your device as predicate while using a substantially different technology, FDA may issue a Not Substantially Equivalent determination under 21 CFR 807.100(b)(2)(ii) if that technology cannot meet the special controls your platform established.
  • Future 510(k) submitters cannot simply adopt your intended use and walk past the special controls. Each element of the classification regulation must be addressed with objective evidence in their submission.

Strategic Implications for De Novo Applicants

Because your De Novo order creates the classification standard, the special controls language you negotiate with FDA during the interactive review process matters enormously — not just for your device, but for the competitive landscape you are defining.

Companies that engage proactively during the De Novo review to shape clear, well-defined special controls create a durable regulatory moat. Those that accept vague or broadly drafted controls may find competitors more easily satisfying them with inferior products. Conversely, overly restrictive controls that your own next-generation device cannot meet can become an internal compliance burden when you seek clearance for a product iteration.

Practical considerations include:

  • Reviewing draft special controls language with both your regulatory and R&D teams before FDA finalizes the order.
  • Assessing whether the performance thresholds in the proposed controls are achievable by your pipeline products, not just the device currently under review.
  • Documenting how your testing protocols map to each special control — this documentation will be reused in future 510(k)s and in responses to any post-market inquiries.
  • Monitoring the Federal Register for finalization of the classification regulation after the grant, and updating your quality system to reference the codified regulation number, not just the De Novo order number.

Post-Market Compliance Is Not a One-Time Exercise

Special controls do not expire after clearance. They attach to the device for its entire commercial life. FDA inspectors reviewing your quality system under 21 CFR Part 820 (or the updated Quality System Regulation aligned with ISO 13485) will evaluate whether your complaint handling, corrective actions, and post-market surveillance activities are consistent with the special controls in your classification regulation. If your De Novo order requires post-market performance monitoring against defined clinical thresholds, that obligation lives in your design history file and your post-market surveillance plan — indefinitely.

Treating special controls as a submission checklist rather than a living compliance obligation is one of the most common and consequential mistakes ADB's practice teams see in post-clearance audits and 483 response engagements.

The Bottom Line

A De Novo authorization is one of the most powerful regulatory outcomes available to a medical device company. It creates your predicate, defines your classification, and sets the terms under which your competitors must play. But that power comes with enduring obligations — to your own device, to your pipeline, and to anyone who follows you into the market. The companies that understand special controls as a strategic and compliance instrument, not just a submission hurdle, are the ones that extract full value from the De Novo pathway.

If you are preparing a De Novo submission, navigating a 510(k) that cites a De Novo predicate, or evaluating whether the special controls in an existing classification regulation apply to your device, ADB Consulting & CRO Inc. can help. Our regulatory practice teams work with device companies at every stage of the FDA pathway — from pre-submission strategy through post-market compliance. Visit adbccro.com to book a free discovery call and get a clear-eyed assessment of where your program stands.

For related guidance, see our De Novo request preparation service.

Prepared by ADB's Regulatory Team

Reviewed by Andre D. Butler, medical device regulatory consultant, CQA, CCRP

ADB's regulatory team brings 20+ years of hands-on FDA regulatory experience guiding medical device companies through 510(k), PMA, De Novo, AI/ML SaMD, and FDA 483 response engagements, with specialization in Section 524B cybersecurity compliance and ISO 13485 quality management systems across cardiovascular, orthopedic, diagnostic, and software-as-a-medical-device categories.

Ready to Navigate the FDA Process with Confidence?

Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.

Book a Free Pathway Call

Or call directly: (888) 450-8607

Explore our flat-fee FDA services →